Bayer
100 Bayer Boulevard
Whippany
New Jersey
07981
United States
793 articles with Bayer
-
The FDA accepted Bayer's supplemental New Drug Application for its proposed oral treatment for metastatic hormone-sensitive prostate cancer.
-
U.S. FDA Accepts Supplemental New Drug Application (sNDA) and Grants Priority Review for NUBEQA® (darolutamide) in Combination with Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
5/3/2022
Bayer today announced the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for the oral androgen receptor inhibitor (ARi) NUBEQA ® .
-
Ginkgo Bioworks to Expand Platform Capabilities in Agricultural Biologicals and Launch Flagship Partnership with Bayer
4/22/2022
Ginkgo Bioworks, the leading horizontal platform for cell programming, announced plans to significantly expand its platform capabilities in agricultural biologicals, from discovery to field.
-
Bayer to Create Ag Biologicals Powerhouse Partnership with Ginkgo Bioworks, Advancing Joyn Bio Technology Platforms
4/22/2022
Bayer announced that the company is pursuing an agreement whereby Ginkgo Bioworks will acquire Bayer’s West Sacramento Biologics Research & Development site and internal discovery and lead optimization platform.
-
Bayer has lured another top oncology expert from GlaxoSmithKline. Tara Frenkl is joining the Germany-based life sciences giant as the new head of oncology development.
-
Toxicities and concerning patient survival data sparked a U.S. Food and Drug Administration advisory committee to recommend shutting the door on single-arm clinical studies of PI3K inhibitors.
-
The U.S. FDA's Oncologic Drugs Advisory Committee is holding a meeting on April 21, 2022, to discuss safety findings across the entire class of PI3K inhibitors for hematological cancers.
-
Bayer Presents New Subgroup Analyses for KERENDIA® (finerenone) for Chronic Kidney Disease Associated With Type 2 Diabetes With or Without History of Atherosclerotic Cardiovascular Disease
4/4/2022
Bayer announced today late-breaking data from prespecified exploratory subgroup analyses of FIDELITY, a prespecified pooled analysis of the Phase III FIDELIO-DKD and FIGARO-DKD trials.
-
Bayer Set to Drive Breakthrough Innovations in the Life Sciences
4/1/2022
Today, Bayer held its first ever Breakthrough Innovation Forum, focusing on longer-term opportunities for health and agriculture leveraging emerging technologies.
-
Bayer to Highlight New Cardiovascular and Renal Data at ACC.22, Including Late-Breaking Presentations for KERENDIA® (finerenone) as Well as Oral Factor XIa Inhibitor (asundexian) Program
3/29/2022
Bayer will present a range of new clinical data at the American College of Cardiology’s 71st Annual Scientific Session (ACC.22), being held April 2-4, 2022, in Washington, D.C.
-
Per Bloomberg: Singapore-based Temask Holdings is calling for the installation of a new chief executive officer at Bayer.
-
Money on the Move: March 16-22
3/23/2022
Most major money moves this week were related to immune therapy companies, including rounds of funding for T cell therapies, allergy therapies and immunomodulation platforms. -
Evotec Receives € 3 m Milestone Payment for Bayer Starting Phase II Clinical Development of DNP Programme
3/21/2022
Evotec SE announced that the Company received a € 3 m milestone payment from Bayer AG as a result of another promising small molecule from the Evotec-Bayer multi-target research alliance advancing into Phase II clinical development as a potential treatment for diabetic neuropathic pain.
-
More pharmaceutical companies are joining to put economic pressure on Russia by suspending some or all operations within that country following the invasion of Ukraine.
-
Bayer to Sell Its Environmental Science Professional Business to Cinven for 2.6 Billion U.S. Dollars
3/10/2022
Bayer and Cinven have entered into a definitive agreement regarding the sale of Bayer’s Environmental Science Professional business for a purchase price of 2.6 billion U.S. dollars, Bayer announced on Thursday.
-
Bayer Submits Applications in the U.S. and EU for Additional Indication of NUBEQA® (darolutamide)
3/9/2022
Bayer Submits Applications in the U.S. and EU for Additional Indication of NUBEQA ® (darolutamide).
-
The trial’s primary endpoint was to assess endometrial health, with additional goals of evaluating the safety and tolerability of the drug.
-
Robert LaCaze is taking over the reins of Mnemo Therapeutics with the goal of overcoming key challenges in CAR-T therapies and driving the company’s lead assets into the clinic.
-
Bayer is heading back to the FDA to seek approval for a new indication of its prostate cancer drug Nubeqa, following positive Phase III results.